Abstract
We compared the outcomes of patients with higher-risk diffuse large B-cell lymphoma (DLBCL) who were treated with either up-front autologous stem cell transplantation (ASCT) or salvage chemotherapy followed by delayed ASCT after relapse. Data for 122 DLBCL patients who underwent ASCT as up-front or salvage treatment were analyzed. The 3-year overall survival (OS) rate in DLBCL patients who underwent up-front ASCT was 76.6%, and the rate for those who underwent delayed ASCT was 60.9% (p = 0.017). In a subgroup analysis of patients with a high-intermediate/high-risk age-adjusted International Prognostic Index, achievement of complete remission translated into improved OS in the up-front ASCT group, whereas patients who achieved partial remission had similar OS rates in both groups. The up-front ASCT group had improved OS in patients aged <50 years or with good performance status, whereas the OS rates of both groups were similar in patients aged ≥ 60 years or with poor performance status. When the OS outcome is analyzed by the number of factors (no complete remission during R-CHOP induction chemotherapy, age ≥ 50 years, and performance status ≥ 2), the 3-year OS rates of patients with zero or one, two, and three clinical factors w...Continue Reading
References
Jan 4, 2001·Journal of the National Cancer Institute·H C Kluin-NelemansJ Thomas
May 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Christian GisselbrechtUNKNOWN Groupe d'Etude des Lymphomes de l'Adulte
Dec 19, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M D CaballeroE Conde
Mar 27, 2004·The New England Journal of Medicine·Noel MilpiedUNKNOWN Groupe Ouest-Est des Leucémies et des Autres Maladies du Sang
May 25, 2006·Medical Oncology·Magdalena AddeAnna Laurell
Nov 16, 2006·Blood·Laurie H SehnJoseph M Connors
Jan 24, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Harmonization Project on Lymphoma
Apr 3, 2007·Cancer Treatment Reviews·Alexander GrebAndreas Engert
Jun 8, 2007·Leukemia·C TarellaUNKNOWN Gruppo Italiano Terapie Innovative nei Linfomi
Nov 1, 2007·Blood·Edo VellengaPeter C Huijgens
Apr 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marita ZiepertMarkus Loeffler
May 7, 2011·Haematologica·Olivier FitoussiChristian Gisselbrecht
Nov 22, 2012·The Lancet Oncology·Norbert SchmitzUNKNOWN German High-Grade Lymphoma Study Group (DSHNHL)
Citations
Jun 22, 2016·Annals of Hematology·Yu Ri KimJin Seok Kim
Oct 27, 2017·Oncotarget·Ying ZhaoDe-Pei Wu
May 14, 2016·Oncotarget·Yinghan SuJie Chen
Apr 15, 2020·Annals of Hematology·Shu-Yun MaQing-Qing Cai